MedTrace Logo

Effectiveness of Recombinant Human Growth Hormone Therapy for Children With PMS

NCT05105685 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 6

Last updated 2022-10-10

No results posted yet for this study

Summary

In summary, this piot study with 6 participants shown that recombinant human growth hormone (rhGH) has a positive effect on the treatment with PMS. In addition, This study indicated that rhGH can improve PMS symptoms via increase the level of serum insulin-like growth factor-1 (IGF-1) and insulin-like growth factor binding protein 3 (IGFBP-3). RhGH may be low cost, more accessible, alternative treatment for PMS.

Conditions

  • Phelan-McDermid Syndrome
  • Growth Hormone Treatment

Interventions

DRUG

recombinant human growth hormone

RhGH treatment was started at 0.1 IU/kg once daily

DRUG

Saline

Saline was started at 0.1 IU/kg once daily as the placebo

Sponsors & Collaborators

  • Affiliated Hospital of Jiangnan University

    lead OTHER

Principal Investigators

  • YueYing Liu, Phd · Affiliated Hospital of Jiangnan University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
1 Year
Max Age
5 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-06-14
Primary Completion
2021-05-12
Completion
2021-06-08

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05105685 on ClinicalTrials.gov